Astria Therapeutics Inc Stock Price, News & Analysis

Astria Therapeutics, Inc. (NASDAQ:ATXS) announced the promotion of Andrea Matthews to Chief Business Officer, elevating her role to enhance the company’s strategic growth. Matthews, who has nearly nine years with Astria, is tasked with overseeing Corporate Strategy, Business Development, Investor Relations, Corporate Communications, and Patient Advocacy. Her leadership is expected to drive the development of STAR-0215, a monoclonal antibody in clinical trials for treating hereditary angioedema. CEO Jill C. Milne highlighted Matthews' contributions to the company’s pivotal developments. The company focuses on creating impactful therapies for rare allergic and immunological diseases.

Astria Therapeutics, Inc. (NASDAQ:ATXS) announced the grant of stock options for 39,300 shares of common stock on April 3, 2023. This grant, made under the 2022 Inducement Stock Incentive Plan, targets new employees as per Nasdaq Listing Rule 5635(c)(4). The options will have an exercise price of $12.93, equivalent to the closing stock price on the grant date. Vesting occurs over four years, with 25% vesting after the first anniversary and the remainder vesting monthly for 36 months, contingent upon continued employment. Astria focuses on rare and niche immunological diseases with its lead program, STAR-0215, targeting hereditary angioedema.

Astria Therapeutics, Inc. (NASDAQ:ATXS) provided a corporate update and financial results for Q4 2022 and the full year. The company is advancing STAR-0215 for hereditary angioedema (HAE) treatment, with promising Phase 1a results showing a potential half-life of up to 117 days. The ALPHA-STAR Phase 1b/2 trial is underway, with proof-of-concept results expected in mid-2024. As of December 31, 2022, Astria reported cash and short-term investments of $226M, ensuring operational funding through mid-2025. The net loss for Q4 was $13.3M, reflecting a slight increase from the previous year.

Astria Therapeutics, Inc. (NASDAQ:ATXS) will announce its fourth quarter and full year 2022 financial results before the Nasdaq Global Market opens on March 22, 2023. CEO Jill C. Milne, Ph.D., will lead a conference call and webcast at 8:30am ET to discuss these results and provide updates on corporate developments. The company's lead program, STAR-0215, is in clinical development for hereditary angioedema. Interested parties can access the webcast through the Astria website. The announcement aims to inform investors and stakeholders of the company’s performance and future outlook.

Astria Therapeutics (NASDAQ:ATXS), a biopharmaceutical company, announced that CEO Jill C. Milne, Ph.D., will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13 at 1:20 PM ET. The presentation will focus on the lead program STAR-0215, a monoclonal antibody being developed for hereditary angioedema. Investors can access a live webcast of the event at this link, with an archived replay available for 30 days on the company's website. Astria aims to provide life-changing therapies for rare allergic and immunological diseases.

Astria Therapeutics, Inc. (NASDAQ:ATXS) has granted stock options to purchase 10,000 shares of its common stock as part of its 2022 Inducement Stock Incentive Plan. This grant was issued on March 1, 2023, to incentivize new employees, with an exercise price set at $12.80, equal to the stock's closing price on the grant date. The options will vest over four years, beginning after the first anniversary of the employees' start date. Astria is focused on developing STAR-0215, a treatment for hereditary angioedema, as part of its mission to deliver therapies for rare allergic and immunological diseases.

Astria Therapeutics (NASDAQ: ATXS) presented promising data from its Phase 1a trial of STAR-0215, a monoclonal antibody targeting hereditary angioedema (HAE), at the American Academy of Allergy Annual Meeting. The results indicate STAR-0215 is well-tolerated with a half-life of up to 117 days, suggesting potential for dosing once every three months. The study showed effective inhibition of plasma kallikrein and no serious adverse events. A Phase 1b/2 trial, ALPHA-STAR, is ongoing with results expected mid-2024. The company aims to deliver life-changing therapies for rare allergic and immunological diseases.

Astria Therapeutics, Inc. (NASDAQ: ATXS) announced its upcoming presentations on STAR-0215, a monoclonal antibody for hereditary angioedema, at the American Academy of Allergy, Asthma, and Immunology Annual Meeting in San Antonio, Texas on February 26, 2023. Presentations by Dr. Chris Morabito and Dr. Nikolaos Biris will unveil critical Phase 1a trial data supporting STAR-0215's efficacy and innovative enzyme inhibition mechanism. The company plans to explore six-month dosing based on preliminary outcomes, with further data anticipated in mid-2024 from ongoing trials. Astria remains committed to developing therapies for rare immunological diseases.